COMP <GO>
AMRX vs MRK // EV/EBITDA & P/E VALUATION
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: AMRX 5
— MRK 10
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $21.51 (+0.75%) • MKT CAP: $7.44B
valuation
21.4x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 74.80% | -37.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 20.70% | -6.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.4x | 15.3x | +6.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 3.42% | +0.21 | AMRX | /fcf-yield <GO> |
| Operating Margin | 13.10% | 34.30% | -21.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 28.10% | -25.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 1.30% | +6.70 | AMRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 5.19 | -1.36 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 56.9 | +10.79 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | AMRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 18.4x | +77.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.44B | $361.02B | -$353.59B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | MRK REV | AMRX GROSS % | MRK GROSS % | AMRX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $65.01B | 36.9% | 74.8% | $269.9M | $12.36B |
| FY 2024 | $2.79B | $64.17B | 36.5% | 76.3% | $243.2M | $18.10B |
| FY 2023 | $2.39B | $60.12B | 44.0% | 44.0% | $237.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
MRK // BETA 0.92